However, as the study was not designed to robustly assess cardiovascular effects and other safety parameters, further study of the safety of coadministration of GXR

and psychostimulants is warranted. Acknowledgments With great sadness, the authors wish to acknowledge the passing of our colleague, Mary Haffey, and recognize her contributions PU-H71 to this article. Funding and Individual Contributions This clinical research was funded by the sponsor, Shire Development LLC (Wayne, PA, USA). Under direction from the authors, Jennifer Steeber PhD [an employee of SCI Scientific Communications & Information (SCI); Parsippany, NJ, USA] provided writing assistance for this publication. Editorial assistance in the form of proofreading, copy editing, and fact checking was also provided by SCI. Jonathan Rubin MD MBA, Carla White BSc CStat, Edward Johnson, Michael Kahn, and Gina D’Angelo PharmD MBA, from Shire Development LLC, and Sharon Youcha MD [a

former employee of Shire Development LLC] also reviewed and edited the Selleck AZD9291 manuscript for scientific accuracy. Additional editorial support was provided check details by Wilson Joe, PhD, of MedErgy (Yardley, PA, USA). Shire Development LLC provided funding to SCI and MedErgy for support in writing and editing this manuscript. Although the sponsor was involved in the design, collection, analysis, interpretation, and fact checking of information, the content of this manuscript, the ultimate interpretation, the accuracy of the study results, and the decision to submit it for publication in Drugs in R&D was made

by the authors independently. Conflict of Interest Disclosures Benno Roesch is affiliated with Advanced Biomedical Research, Inc. (Hackensack, NJ, USA). Mary Corcoran, Jaideep Purkayastha, Philip Wang, and James Ermer are employees of Shire and hold stock and/or stock options in Shire. Jennifer Fetterolf and Peter Preston are consultants of Shire. Mary Haffey was an employee of Rebamipide Shire and held stock and/or stock options in Shire. Patrick Martin is an employee of Shire. Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. The exclusive right to any commercial use of the article is with Springer. References 1. Adler LA, Reingold LS, Morrill MS, et al. Combination pharmacotherapy for adult ADHD. Curr Psychiatry Rep. 2006;8(5):409–15.PubMedCrossRef 2. Popper CW. Combining methylphenidate and clonidine: pharmacologic questions and news reports about sudden death. J Child Adolesc Psychopharmacol. 1995;5(3):157–66.CrossRef 3. Brown TE. Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: four case reports. J Child Adolesc Psychopharmacol. 2004;14(1):129–36.PubMedCrossRef 4.